Alto Neuroscience (ANRO) Operating Expenses (2023 - 2026)

Alto Neuroscience has reported Operating Expenses for 4 years, with the latest figure at $27.1 million in Q1 2026.

• Quarterly Operating Expenses rose 73.12% year-over-year to $27.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.8 million (up 11.34% YoY) and the FY2025 annual result came in at $66.4 million, down 3.27% from the prior year.
• Operating Expenses grew to $27.1 million in Q1 2026 per ANRO's latest filing, from $17.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $27.1 million in Q1 2026 and troughed at $7.2 million in Q1 2023.
• A 4-year average of $15.4 million and a median of $15.7 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 101.0% in 2024, then dropped 20.84% in 2025.
• Over 4 years, Operating Expenses stood at $11.8 million in 2023, then soared by 44.47% to $17.0 million in 2024, then rose by 0.34% to $17.1 million in 2025, then soared by 59.12% to $27.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $27.1 million, $17.1 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.